Cancer Patient Survival Rates

While we are proud to publicise our survival statistics for various common cancers, we don’t think of our patients as statistics. Our patients are individuals with specific needs and health complexities. No two patients fit in the same box.

Understanding Survival Rates

Statistics collected about any cancer don’t take into consideration information about individual cases. They do not consider age groups, whether a patient has had previous illness, the extent of cancer at diagnosis, complications experienced, previous treatments or adverse reactions to these treatments or any damage left behind by them. Also not taken into account are patients’ lifestyle choices or genetics.  

No one is living the same same cancer as someone else

Creating a statistic or success rate represents a linear approach to cancer, by just looking at this problem from the tumor view, without acknowledging each patient’s unique background.

Nonetheless, our numbers are meant to present a general understanding of what cancers we see and how successful our outcomes have been. More than 50% of our survivors live more than two years. 

Cancer TypeCase NumberStage IStage IIStage IIIStage IVBenefit Rate (%)
Lung Cancer1067339740842890%
Pancreatic Cancer195311328793%
Breast Cancer12523166788%
Ovarian Cancer520392892%
Colon Cancer470152887%
Cervical Cancer241151296%
Bladder Cancer110104100%

The graph below shows the number of months patients have survived after receiving any treatment at our Center.

CR= Complete Response | PR= Partial Response | SD=Stable | PD=Progress | Effect rate= CR+PR | Benefit Rate=CR+PR+SD

Including Stage 4 patients, over 90% of our patients have been in the 80-90% benefit rate.

Cancer TypeCase NumberStage IStage IIStage IIIStage IVNot StagedCRPRSDPDEffect Rate (%)Benefit Rate (%)
Lung Cancer10673397408428101172986421103090
Pancreatic Cancer19531132876201416813793
Breast Cancer1252316673733374152988
Ovarian Cancer5203928120123642392
Colon Cancer470152813073461587
Cervical Cancer24115125331712596
Bladder Cancer1101046029018100
Esophageal Cancer1085103133633415855242711772793
Liver Cancer463896121103135081351311893
Gastric Cancer169618318628027125171690
Rectal Cancer1334128476202398121791
Cardiac Cancer1101143240232267482593
Kidney Cancer33202151402265685
Thyroid Cancer2402351402184883
Hypopharyngeal Cancer2111595041521990
Nasopharyngeal Cancer1602734031121988
Endometrial Cancer140009513732979
Laryngeal Cancer110024502721882
Parotid Gland Cancer100005503613090
Other Cancer242101553173244173241990

Side Effects: No except fever

We’ve collected statistics about the benefits of our treatments for over 20 years and compared them to traditional treatments.

IndicationSurvival RatesConventional Standard CareIntratumoral ChemoteraphyOur Treatments
(at least 1 of our treatments)
Advanced Pancreatic Cancer

(120 cases)

6 Month Survival Rate (%)27%18%77%
12 Month Survival Rate (%)13%9%57%
Advanced Lung Cancer

(259 cases)

6 Month Survival Rate (%)39%61%95%
12 Month Survival Rate (%)23%33%86%
2 Year Survival Rate (%)11%7%37%
Liver Cancer

(221 cases)

6 Month Survival Rate (%)NA32%61%
12 Month Survival Rate (%)17%19%30%

Traditional survival rates sources: 


  1. “Use of Hapten Combined Cytotoxic Drugs for Enhancing Therapeutic Effect in Advanced Stages of Pancreatic Cancer,” Journal of Liver Research, Disorders & Therapy, December 30, 2015
  2. “Hapten Improved Overall Survival Benefit in Late Stages of Non-Small Cell Lung Cancer (NSCLC) by at least one of our Functional Oncology available treatments (Our Treatments), Therapy With and without Radiation Therapy,” Journal of Cancer Prevention & Current Research, February 8, 2016
  3. Journal of Hepatocellular Carcinoma, 2015:2 1-12 
  4. SEER data, based on compiled 2007-2013data